tiprankstipranks
Trending News
More News >
Bioceres Crop Solutions (BIOX)
NASDAQ:BIOX

Bioceres Crop Solutions (BIOX) AI Stock Analysis

Compare
269 Followers

Top Page

BIOX

Bioceres Crop Solutions

(NASDAQ:BIOX)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$1.50
▼(-4.46% Downside)
Bioceres Crop Solutions is facing a challenging financial environment with declining revenues and profitability. While there are improvements in cash flow and cost efficiency, high leverage and negative returns on equity are significant concerns. The technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio. The earnings call provided some positive insights into margin improvements, but these are overshadowed by revenue declines and debt issues.
Positive Factors
Gross Margin Expansion
The significant expansion in gross margin indicates improved product mix and operational efficiency, which can enhance long-term profitability.
Leadership Strengthening
New leadership appointments can strengthen strategic and financial governance, potentially improving market position and operational resilience.
Cash Flow Improvement
Improved cash flow generation enhances financial flexibility and supports strategic investments, crucial for long-term growth and stability.
Negative Factors
Revenue Decline
A significant decline in revenue can impact the company's ability to invest in growth and maintain competitive positioning.
Debt Dispute
Ongoing legal disputes over debt can strain financial resources and distract management, potentially affecting long-term strategic focus.
Market Challenges in Argentina
Macroeconomic challenges in key markets like Argentina can limit growth opportunities and affect revenue stability over the medium term.

Bioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)

Bioceres Crop Solutions Business Overview & Revenue Model

Company DescriptionBioceres Crop Solutions (BIOX) is a biotechnology company focused on agricultural solutions that enhance crop productivity and sustainability. The company operates primarily in the agricultural biotechnology sector, offering a range of products and services that include seed traits, crop protection, and biological solutions. Bioceres is known for its innovative approach to enhancing crop resilience against environmental challenges, optimizing resource use, and improving overall agricultural efficiency.
How the Company Makes MoneyBioceres Crop Solutions generates revenue through several key streams. First, it sells proprietary seed traits that are designed to improve crop performance and resistance to various stresses. Second, the company offers crop protection products, which include biological and chemical solutions aimed at safeguarding crops from pests and diseases. Additionally, Bioceres has developed partnerships with agricultural distributors and other industry players, which help expand its market reach and enhance its product offerings. The company also benefits from licensing agreements and collaborations in research and development, allowing it to capitalize on its innovations while sharing the financial risks associated with new product development. Overall, Bioceres' revenue model is built on a combination of direct sales, partnerships, and strategic collaborations that leverage its expertise in agricultural biotechnology.

Bioceres Crop Solutions Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows how much revenue each business segment contributes, highlighting areas of strength and potential growth within Bioceres Crop Solutions' diverse operations.
Chart InsightsBioceres Crop Solutions is experiencing a challenging period, with a notable decline in revenues across all segments, particularly in Seed and Integrated Products. The earnings call highlighted a 40% drop in fourth-quarter revenues, driven by macroeconomic challenges in Argentina and reduced seed sales. Despite these setbacks, the company is focusing on cash flow generation and cost control, with international sales showing resilience, especially in Brazil and the U.S. Bioceres aims to stabilize financially and leverage strategic partnerships to navigate less volatile markets.
Data provided by:The Fly

Bioceres Crop Solutions Earnings Call Summary

Earnings Call Date:Nov 12, 2025
(Q1-2026)
|
% Change Since: |
Next Earnings Date:Feb 05, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with notable improvements in gross margin and adjusted EBITDA, supported by cost reductions. However, these were counterbalanced by significant declines in revenue across multiple segments and an ongoing debt dispute. The company is focusing on building a more resilient and profitable model despite a complex operating environment.
Q1-2026 Updates
Positive Updates
Gross Margin Expansion
Gross margin expanded significantly by 650 basis points to 47% compared to 40% in the same quarter last year, reflecting improved product mix and margin expansion.
Operating Profit and Adjusted EBITDA Improvement
A significant decline in SG&A costs resulted in meaningful improvements in operating profits and a 61% increase in adjusted EBITDA, reaching $13.6 million compared to $8.5 million in the same period last year.
SG&A Cost Reduction
Both variable and fixed SG&A costs declined significantly, achieving 50% of the top of the expected annualized savings range in just one quarter.
Improved Net Debt to Adjusted EBITDA Ratio
Despite the challenging environment, the net debt to adjusted EBITDA ratio improved to 6.8x.
Negative Updates
Decline in Total Revenues
Total revenues for the quarter were $77.5 million, a 17% decline from the same period last year, primarily due to strategic transitions and sales timing effects in Latin America.
Challenges in Crop Protection and Seed Segments
Crop Protection revenues fell by 16% to $39.9 million, and Seed and Integrated Products revenues decreased by 37% to $12.6 million, mainly due to sluggish demand in Argentina and strategic unwinding of certain programs.
Debt Dispute
The company is undergoing a dispute with holders of its secured convertible and nonconvertible notes, resulting in a classification of certain debts as current.
Company Guidance
During the Bioceres Crop Solutions Fiscal First Quarter 2026 earnings call, Federico Trucco, CEO, highlighted key financial metrics and strategic priorities. Despite a 17% decline in total revenues to $77.5 million, the company achieved a gross profit of $36 million, maintaining a robust gross margin expansion of 650 basis points to 47%. The company's adjusted EBITDA surged 61% to $13.6 million, driven by a $5.9 million reduction in operating costs. Bioceres is focused on maintaining a gross margin above 40%, reducing annual SG&A by $10-12 million, and achieving profitability with adjusted EBITDA above 20% of sales. The company also reported a significant decline in revenues from Crop Protection and Seed and Integrated Products segments, but noted improvements in cost efficiency and product mix. Current debt was reported at $188.7 million, with a net financial debt of $225.9 million, while the net debt to adjusted EBITDA ratio improved to 6.8x. The company is committed to operating with discipline, focusing on profitability, liquidity, and capital efficiency amid a challenging environment.

Bioceres Crop Solutions Financial Statement Overview

Summary
Bioceres Crop Solutions faces significant challenges in revenue growth and profitability, with a negative net profit margin and declining revenues. Improvements in cash flow generation are noted, but high leverage and negative returns on equity remain concerns.
Income Statement
45
Neutral
Bioceres Crop Solutions has experienced a decline in revenue growth, with a negative growth rate of -13.05% in the most recent year. The company also reported a negative net profit margin of -15.54%, indicating challenges in profitability. The gross profit margin remains stable at around 39%, but the negative EBIT margin suggests operational inefficiencies. Overall, the income statement reflects a challenging financial environment with declining revenues and profitability.
Balance Sheet
50
Neutral
The company's debt-to-equity ratio has improved from previous years, indicating better leverage management, but remains a concern with a high level of total debt. The return on equity is currently negative, reflecting the company's struggle to generate profit from shareholders' equity. The equity ratio shows a moderate level of equity financing. Overall, the balance sheet shows some improvement in leverage but highlights ongoing profitability challenges.
Cash Flow
60
Neutral
Bioceres Crop Solutions has shown significant improvement in free cash flow growth, with a 65.56% increase, indicating better cash generation capabilities. However, the operating cash flow to net income ratio is not available, and the free cash flow to net income ratio is low, reflecting challenges in converting income into cash flow. Overall, the cash flow statement shows positive trends in cash generation but highlights the need for better profitability conversion.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue333.40M333.30M464.83M419.45M328.46M206.70M
Gross Profit130.00M130.20M181.59M180.25M126.44M90.88M
EBITDA15.19M13.59M55.45M72.38M47.91M43.70M
Net Income-51.00M-51.80M3.24M18.78M-7.20M-6.87M
Balance Sheet
Total Assets763.65M763.65M852.55M818.06M518.22M394.59M
Cash, Cash Equivalents and Short-Term Investments34.74M34.74M56.17M60.05M38.61M46.78M
Total Debt276.61M276.61M270.95M257.41M169.79M174.58M
Total Liabilities468.43M468.43M501.17M487.56M359.92M304.30M
Stockholders Equity262.81M262.81M315.30M298.85M127.61M67.74M
Cash Flow
Free Cash Flow28.71M35.30M18.93M-19.97M-26.51M-20.13M
Operating Cash Flow39.87M49.91M41.72M2.59M-17.52M-6.21M
Investing Cash Flow-6.13M-6.13M-28.73M-25.73M2.90M-8.31M
Financing Cash Flow-50.71M-50.71M-10.06M32.95M14.82M7.36M

Bioceres Crop Solutions Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.57
Price Trends
50DMA
1.66
Negative
100DMA
2.14
Negative
200DMA
3.30
Negative
Market Momentum
MACD
-0.04
Negative
RSI
46.69
Neutral
STOCH
44.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Negative. The current price of 1.57 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.66, and below the 200-day MA of 3.30, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.69 is Neutral, neither overbought nor oversold. The STOCH value of 44.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOX.

Bioceres Crop Solutions Risk Analysis

Bioceres Crop Solutions disclosed 68 risk factors in its most recent earnings report. Bioceres Crop Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Certain of the Rizobacter shares we own are subject to a judicial injunction that, if decided unfavorably to us, would require us to surrender part of our interest in Rizobacter thereby reducing our equity interest in Rizobacter. Q2, 2024
2.
The disposition or sale of our ordinary shares may be subject to taxation in Argentina. Q2, 2024
3.
Our share repurchase program may reduce liquidity. Q2, 2024

Bioceres Crop Solutions Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
50
Neutral
$4.83M-0.64-64.08%-1.80%15.74%
49
Neutral
$111.00M-2.16-20.52%-27.90%-4194.67%
46
Neutral
$17.49M-21.69-21.82%-104.92%
45
Neutral
$122.98M-40.84%-4.29%-276.74%
44
Neutral
$110.38M
41
Neutral
$120.07M-200.22%45.88%43.12%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BIOX
Bioceres Crop Solutions
1.57
-5.20
-76.81%
AVD
American Vanguard
4.32
-0.61
-12.37%
SEED
Origin Agritech
1.44
-0.88
-37.93%
RKDA
Arcadia Biosciences
3.64
-2.56
-41.29%
BHST
BioHarvest Sciences
5.30
-0.85
-13.82%
LVRO
Lavoro Limited
0.61
-4.45
-87.94%

Bioceres Crop Solutions Corporate Events

Bioceres Crop Solutions Releases Q3 2025 Financial Update
Nov 26, 2025

Bioceres Crop Solutions Corp. released its unaudited interim condensed consolidated financial statements for the periods ending September 30, 2025, and June 30, 2025. The financial report indicates a decrease in total assets from $763.6 million to $734.9 million, and a reduction in total liabilities from $468.4 million to $446.5 million. This financial update provides stakeholders with insights into the company’s current financial health and operational adjustments over the recent quarter.

Bioceres Crop Solutions Reports Q1 2026 Financial Results Amid Strategic Transition
Nov 13, 2025

Bioceres Crop Solutions reported its fiscal first quarter 2026 financial results, with total revenues of $77.5 million, marking a 17% decline year-over-year. Despite the revenue drop due to strategic reductions in low-margin sales and seed model transition, the company achieved a gross margin expansion from 40% to 47%, reflecting a more profitable product mix. The net loss widened to $7.5 million, but operating profit and adjusted EBITDA saw significant improvements, driven by cost discipline and restructuring efforts. The company remains focused on enhancing capital structure and financial flexibility amidst challenging market conditions in Argentina.

Bioceres Crop Solutions Faces Legal Action Over Alleged Defaults
Nov 12, 2025

On November 10, 2025, Bioceres Crop Solutions received an Acceleration Notice from its noteholders, alleging defaults under its Convertible and Non-Convertible Note Purchase Agreements. Subsequently, on November 11, 2025, these noteholders initiated legal proceedings against Bioceres in the New York Supreme Court, seeking full payment of outstanding amounts. Bioceres disputes the allegations and intends to defend its position vigorously, reserving all rights against the noteholders.

Bioceres Crop Solutions Strengthens Leadership with New Appointments
Nov 6, 2025

On November 5, 2025, Bioceres Crop Solutions Corp. announced the appointment of Mr. Simon Vumbaca to its Board of Directors and Mr. Alejandro Villafane as the Principal Accounting Officer. Mr. Vumbaca brings expertise in high-stakes strategies and governance, while Mr. Villafane will oversee the company’s accounting functions. These appointments are expected to strengthen Bioceres’ strategic and financial leadership, potentially enhancing its market position and operational resilience.

Bioceres Crop Solutions Faces Board Resignation Amid Financial Dispute
Oct 2, 2025

On September 30, 2025, Noah Kolatch resigned from the board of directors of Bioceres Crop Solutions Corp. following a reservation of rights letter from Jasper Lake Ventures One LLC. The letter, dated September 25, 2025, alleged several defaults under a Note Purchase Agreement. In response, Bioceres disputed these claims, emphasizing the importance of dialogue with Jasper Lake to address any concerns. The company remains committed to improving its commercial and financial performance while maintaining its focus on delivering innovative agricultural solutions.

Bioceres Crop Solutions Faces Challenging FY25 Amid Argentine Market Pressures
Sep 9, 2025

Bioceres Crop Solutions Corp. announced its financial results for the fourth fiscal quarter and full year 2025, highlighting a challenging year due to macroeconomic pressures in Argentina. The company reported a 40% decline in quarterly revenues to $74.7 million and a 28% decrease in annual revenues to $335.3 million, primarily due to weaker demand in Argentina and a strategic shift in its seed business. Despite these challenges, Bioceres is adjusting its cost structure and investment strategies to mitigate impacts, aiming for a 10-12% reduction in operating expenses and a significant cut in CAPEX and R&D investments. The company remains optimistic about future conditions and is taking steps to strengthen governance and financial management.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 30, 2025